The treatment with αCD25-m2a reduced the fraction of CD25-expressing cells in the CD4+ T cell compartment (Figure 2B,C), decreased the percentage of CD4+FoxP3+ Tregs (Figure 2C), and increased the Teff/Treg ratios (Figure 2C) in the blood, draining the lymph nodes and tumor. Here, FOXP3 is linked to neoplasm.